Buprenorphine for Opioid Dependence

Interventions For Addiction

Volumn , Issue , 2013, Pages 417-426

  Gordon, Adam J ^a   Krumm, Margaret M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884445567     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-398338-1.00044-0     Document Type: Chapter

References (18)

1. Alford D.P., LaBelle C.T., Richardson J.M., O'Connell J.J., Hohl C.A., Cheng D.M., Samet J.H. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. Journal of General Medicine 2007, 22(2):171-176.
2. Barnett P.G. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009, 104(6):982-992.
3. Bridge T.P., Fudala P.J., Herbert S., Leiderman D.B. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Dependence 2003, 70(Suppl. 2):S79-S85.
4. Center for Substance Abuse Treatment Treatment Improvement Protocol 40: Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction 2004, Department of Health and Human Services, Rockville, Maryland.
5. Fiellin D.A., Kleber H., Trumble-Hejduk J.G., McLellan A.T., Kosten T.R. Consensus statement on office-based treatment of opioid dependence using buprenorphine. Journal of Substance Abuse Treatment 2004, 27(2):153-159.
6. Fiellin D.A., O'Connor P.G. Office-based Treatment of Opioid Dependent Patients. New England Journal of Medicine 2002, 347(11):339-345.
7. Fudala P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., Collins J., Raisch D., Casadonte P., Goldsmith R.J., Ling W., Malkerneker U., McNicholas L., Renner J., Stine S., Tusel D. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 2003, 349(10):949-958.
8. Gowing L., Ali R., White J.M. Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2009, 3. CD002025.
9. Gruber V.A., McCance-Katz E.F. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Current HIV/AIDS Reports 2010, 7(3):152-160.
10. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine 2000, 343(18):1290-1297.
11. Johnson R.E., Strain E.C., Amass L. Buprenorphine: how to use it right. Drug Alcohol Dependence 2003, 70(Suppl. 2):S59-S77.
12. Jones H.E., Kaltenbach K., Heil S.H., Stine S.M., Coyle M.G., Arria A.M., O'Grady K.E., Selby P., Martin P.R., Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine 2010, 363(24):2320-2331.
13. Kraus M.L., Alford D.P., Kotz M.M., Levounis P., Mandell T.W., Meyer M., Salsitz E.A., Wetterau N., Wyatt S.A. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid Addiction. Journal of Addiction Medicine 2011, 5(4):254-263.
14. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2008, 2. CD002207.
15. Oliva E.M., Maisel N.C., Gordon A.J., Harris A.H. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Current Psychiatry Reports 2011, 13(5):374-381.
16. - National Institute on Drug Abuse. http://www.nida.nih.gov.
17. - PCSSB. http://www.pcssb.org.
18. - SAMHSA. http://www.buprenorphine.samhsa.gov.